Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Mark Peterson CPA who wrote (683)	3/31/1999 5:58:00 PM
From: Captain Jack	Respond to of 942

Mark--- I have been playing with a few to keep from being angry here and keeping the wife in the malls... A happy wife is a good wife...

To: Mark Peterson CPA who wrote (683)	4/6/1999 10:22:00 PM
From: Captain Jack	Respond to of 942

Mark--- I wonder how this would hurt if it ever happens... WHITEHOUSE STATION, N.J. (CBS.MW) -- Merck & Co. is considering developing an over-the-counter version of its top-selling Mevacor cholesterol drug. If it's successful in the move, the new version would be the first such cholesterol medicine to be available without a prescription, said John Doorley, a spokesman for Whitehouse Station, N.J.-based Merck (MRK), the No.1 drug maker in the U.S. Developing an over-the-counter version of the drug "would be a strategy to help deal with" its patent expiring in 2001